drug fraud

The Associated Press

In a "landmark" legal case, the pharmaceutical giant GlaxoSmithKline pled guilty last week to engaging in fraudulent, criminal behavior which included covering up adverse drug side-effects, promoting ineffective therapies and hiding unfavorable data — and will pay a record $3 billion in fines.

An aspect of the story that seems to be underreported is that one high-profile Glaxo executive alleged to have engaged in misbehavior is Tachi Yamada, former head of global health for the Bill & Melinda Gates Foundation who was before that head of research and development for GSK.

Read more on Humanosphere.